IDEXX Laboratories (IDXX) BofA Securities Animal Health Summit summary

Key financial and operational highlights

• Achieved 12% organic revenue growth in Q4 2025, supporting double-digit growth for the full year and strong operating margin improvement.

• Record premium instrument placements, with inVue Dx Analyzer exceeding 6,400 placements in 2025, driving recurring revenue growth.

• International business sustained double-digit growth, while U.S. clinical visits declined by 1.7%.

• Operating margin improved by 90 basis points year-over-year, with a 2026 target of 30-80 basis points expansion.

• 2026 guidance includes 8%-10% recurring revenue growth and 5,500 planned instrument placements.

Innovation and product development

• inVue Dx and Cancer Dx platforms drove significant growth, with over 6,000 placements and 18% of Cancer Dx customers new to the reference labs.

• FNA for mast cell tumor detection launched as a controlled rollout, with plans to expand to additional indications.

• Cancer Dx platform expanded to include lymphoma and mast cell tumor detection, with further menu additions planned.

• Innovation strategy focuses on incremental platform extensions and affordability, supporting high customer retention.

• Ongoing R&D investments aim to accelerate the pace of new diagnostic capabilities.

Market trends and sector dynamics

• Sector faces continued headwinds from declining wellness visits, attributed to consumer inflation and discretionary spending constraints.

• Non-wellness visits, accounting for 60% of clinical visits, remain stable and drive higher diagnostic utilization.

• Aging pet population seen as a secular growth driver, with increased diagnostic needs as pets mature.

• Clinic consolidators and macroeconomic factors impact pricing and demand, but long-term visit growth is expected to return.

• No significant regulatory intervention in the U.S. veterinary market anticipated, with affordability of diagnostics emphasized.